Projects

The projects we work on and those we have completed are the best references for our research work. Fraunhofer SCAI is involved in numerous projects funded by the German Federal Government and the European Commission. The list below presents the projects chronologically – new projects first. You can sort the list by selecting categories.

Do you have any questions? Please feel free to write us:

marketing@scai.fraunhofer.de

Reset
  • The main objective of the ETHCSTWIN initiative is to establish a collaborative network between the Institute of Ethnopharmacological Studies and Phytotherapy (IESP, Athens) and two renowned academic research teams from Italy (UNISG, Pollenzo) and Germany (Fraunhofer SCAI), as well as the biotech SME Pangea Botanica and the University of Prishtina. The goal is to integrate the knowledge of ethnopharmacology into novel computational and digital systems, focusing on the development of a rich portfolio of complex methods and tools, including the analysis of large data sets and the restoration of tangible and intangible heritage.

    more info
  • Fraunhofer SCAI coordinates the COMMUTE project, backed by a grant from the European Commission. Over the next four years, an interdisciplinary team of top-tier experts will explore whether COVID-19 infections increase the risk of acquiring neurodegenerative diseases. An innovative AI-driven system is being developed to provide tailored risk assessments for individuals who have recovered from COVID-19.

    more info
  • Recent years have seen an explosion in health data generation from diverse sources. This data has the potential to help advance both research and patient care. However, accessing, integrating, and analyzing it is exceptionally challenging. IDERHA aims to set up an open platform that will facilitate the integration and analysis of diverse types of health data. The platform will link up multiple public and private data sources and implement interoperable tools and services to enable key groups, such as doctors, patients, and researchers, to use the data. To focus their efforts, the IDERHA team will use lung cancer as a use case to design the platform.

    more info
  • Patients with severe psychiatric disorders such as schizophrenia, bipolar disorder and clinical depression often develop resistance to drug therapy. Even when the early signs of treatment resistance (TR) are detected, patients must undergo lengthy procedures before medical professionals can prescribe adequate pharmaceutical care. The EU-funded Psych-STRATA project intends to analyse extensive clinical, genetic and biological data of psychiatric patients to establish criteria for early detection of TR. Based on the findings, it will propose treatment strategies for patients at risk of TR. The project will further create machine learning models that can predict TR risk and patient response to treatment, thus assisting medical professionals in providing more personalised treatment.

    more info
  • REMEDi4ALL – Drug repurposing

    EU-project / Project start  / September 01, 2022

    REMEDi4ALL aims to make a significant leap forward in drug repurposing. This promising approach to drug development, consisting of identifying, testing, and validating new therapeutic indications for existing medications, is a developing field but faces numerous barriers and systemic inefficiencies. Still, its potential to significantly bring down times and costs of drug development - it focuses on already approved, discontinued, shelved or investigational therapeutics - makes this novel strategy attractive for rare and neglected conditions, cancer, emerging public health threats such as COVID-19 or new drug combinations. It also translates into more sustainable health systems.

    more info